Compare · NVO vs SHPH
NVO vs SHPH
Side-by-side comparison of Novo Nordisk A/S (NVO) and Shuttle Pharmaceuticals Holdings Inc. (SHPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SHPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 6543.6x SHPH ($26.5M).
- NVO has hit the wire 3 times in the past 4 weeks while SHPH has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for SHPH).
- Company
- Novo Nordisk A/S
- Shuttle Pharmaceuticals Holdings Inc.
- Price
- -
- -
- Market cap
- $173.66B
- $26.5M
- 1M return
- -10.14%
- -
- 1Y return
- -30.36%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest SHPH
- SEC Form 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.
- Amendment: Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Shuttle Pharmaceuticals Holdings Inc.
- Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.
- Amendment: Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Shuttle Pharmaceuticals Holdings Inc.